Marc Kozin joined the Dicerna board of directors in 2019. Previously, Mr. Kozin was a Career Strategy Consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012.
Mr. Kozin began his career at L.E.K. in 1987 by helping to establish the firm’s Boston office. He has over 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management both domestically and internationally. He also led the development of L.E.K.’s industry-leading life science strategic planning practice.
Mr. Kozin is Lead Director of UFP Technologies, where he has served as a Director since 2006. In January 2013, he joined the strategy advisory board of HealthCare Royalty Partners, where he is Vice Chairman. He also serves as Chairman of the Board of VBL Therapeutics. On the non-profit side, he serves on the board of The Greenlight Fund.
Since 2012, Mr. Kozin has served on the boards of Endocyte, a small molecule-targeted therapeutic company since sold to Novartis; Dyax, an integrated biotechnology company since sold to Shire; OvaScience, a fertility company since merged with Millendo Therapeutics; and Flex Pharmaceuticals.